Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A. Allgäuer M, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Transl Lung Cancer Res. 2018. PMID: 30505715 Free PMC article. Review.
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives.
Wessels S, Muley T, Christopoulos P, Meister M, Heinzmann-Groth I, Warth A, Herpel E, Hummler S, Klingmüller U, Kuon J, Heussel CP, Eberhardt R, Herth FJF, Winter H, Bischoff H, Stenzinger A, Reck M, Huber RM, Thomas M, Schneider MA. Wessels S, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2020 Aug;9(4):1000-1014. doi: 10.21037/tlcr-20-137. Transl Lung Cancer Res. 2020. PMID: 32953480 Free PMC article.
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.
Li J, Zhang B, Zhang Y, Xu F, Zhang Z, Shao L, Yan C, Ulivi P, Denis MG, Christopoulos P, Thomas de Montpréville V, Bernicker EH, van der Wekken AJ, Wang C, Yue D. Li J, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2021 Mar;10(3):1525-1535. doi: 10.21037/tlcr-21-160. Transl Lung Cancer Res. 2021. PMID: 33889527 Free PMC article.
Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
Kriegsmann K, Zgorzelski C, Muley T, Christopoulos P, Thomas M, Winter H, Eichhorn M, Eichhorn F, von Winterfeld M, Herpel E, Goeppert B, Stenzinger A, Herth FJF, Warth A, Kriegsmann M. Kriegsmann K, et al. Among authors: christopoulos p. BMC Cancer. 2021 May 1;21(1):486. doi: 10.1186/s12885-021-08140-9. BMC Cancer. 2021. PMID: 33933015 Free PMC article.
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Kazdal D, Rempel E, Oliveira C, Allgäuer M, Harms A, Singer K, Kohlwes E, Ormanns S, Fink L, Kriegsmann J, Leichsenring M, Kriegsmann K, Stögbauer F, Tavernar L, Leichsenring J, Volckmar AL, Longuespée R, Winter H, Eichhorn M, Heußel CP, Herth F, Christopoulos P, Reck M, Muley T, Weichert W, Budczies J, Thomas M, Peters S, Warth A, Schirmacher P, Stenzinger A, Kriegsmann M. Kazdal D, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2021 Apr;10(4):1666-1678. doi: 10.21037/tlcr-20-1168. Transl Lung Cancer Res. 2021. PMID: 34012783 Free PMC article.
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma.
Fisch D, Bozorgmehr F, Kazdal D, Kuon J, Klotz LV, Shah R, Eichhorn F, Kriegsmann M, Schneider MA, Muley T, Stenzinger A, Bischoff H, Christopoulos P. Fisch D, et al. Among authors: christopoulos p. Front Oncol. 2021 Jul 8;11:673901. doi: 10.3389/fonc.2021.673901. eCollection 2021. Front Oncol. 2021. PMID: 34307143 Free PMC article.
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Brueckl WM, et al. Among authors: christopoulos p. Transl Lung Cancer Res. 2021 Jul;10(7):3093-3105. doi: 10.21037/tlcr-21-197. Transl Lung Cancer Res. 2021. PMID: 34430350 Free PMC article.
292 results